Key result
A high atherogenic index of plasma was independently associated with an increased risk of major adverse cardiovascular events compared to a low index in patients with type 2 diabetes mellitus.
Why the study?
The predictive utility of the atherogenic index of plasma was unknown among patients with type 2 diabetes mellitus.
Does a high atherogenic index of plasma (AIP) predict an increased risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus?
Observational (n=10,251)
Yes
Does a high atherogenic index of plasma (AIP) predict an increased risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
The atherogenic index of plasma (AIP) is an independent prognostic biomarker that can predict the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Background Previous studies have reported the prognostic value of the atherogenic index of plasma (AIP) in the course of atherosclerosis and other cardiovascular diseases (CVDs). However, the utility of the AIP for prediction is unknown among patients with type 2 diabetes mellitus (T2DM). Methods This was a secondary analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study which randomized 10,251 patients with long-lasting T2DM. ROC curve analysis was used to determine an optimal threshold for AIP and the study population was divided into high and low AIP groups. Univariate and multivariate Cox proportional hazards regression analyses were used to find the association between AIP and primary (MACEs) and second outcomes (all-cause mortality). Stratified analyses were performed to control the confounding factors. Results AIP was an independent risk factor for the prognosis of T2DM (HR = 1.309; 95% CI, 1.084–1.581; P = 0.005). The threshold for AIP was determined to be 0.34 among the study population. After adjustments for confounding factors, multivariate analysis showed that AIP was associated with the risk of MACEs (Model 1: HR = 1.333, 95%CI: 1.205–1.474, P ༜0.001; Model 2: HR = 1.171, 95%CI: 1.030–1.333, P = 0.016; Model 3: HR = 1.194, 95%CI: 1.049–1.360, P = 0.007) and all-cause mortality (Model 1: HR = 1.184, 95%CI: 1.077–1.303, P ༜0.001), especially cardiovascular deaths (Model 1: HR = 1.422, 95%CI: 1.201–1.683, P ༜0.001; Model 3: HR = 1.264, 95%CI: 1.015–1.573, P = 0.036) and nonfatal myocardial infarction (Model 1: HR = 1.447, 95%CI: 1.255–1.669, P ༜0.001; Model 2: HR = 1.252, 95%CI: 1.045–1.499, P = 0.015; Model 3: HR = 1.284, 95%CI: 1.071–1.539, P = 0.007). Subgroup stratified analyses showed that AIP might interact with gender, a classical risk factor of cardiovascular events. Conclusions Our study showed that AIP might be a strong biomarker that could be used to predict the risk of cardiovascular events in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2021) conducted an observational in Type 2 diabetes mellitus (n=10,251). High atherogenic index of plasma (AIP ≥ 0.34) vs. Low atherogenic index of plasma (AIP < 0.34) was evaluated on Major adverse cardiovascular events (MACEs) (HR 1.194, 95% CI 1.049-1.360, p=0.007). A high atherogenic index of plasma was independently associated with an increased risk of major adverse cardiovascular events compared to a low index in patients with type 2 diabetes mellitus.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: